Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 601 to 615 of 663 results for diabetes

  1. Lipid disorders: FH assessment and diagnosis (historical readings) (IND260)

    This indicator covers the percentage of patients with a total cholesterol reading greater than 7.5 mmol/litre when aged 29 years or under, or greater than 9.0 mmol/litre when aged 30 years or over, who have been: diagnosed with secondary hyperlipidaemia, or clinically assessed for familial hypercholesterolaemia, or referred for assessment for familial hypercholesterolaemia, or genetically diagnosed with familial hypercholesterolaemia. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM244

  2. Cardiovascular disease prevention: cardiovascular risk assessment for people newly diagnosed with hypertension or T2DM (IND161)

    This indicator covers the percentage of patients aged between 25 and 84 years with a new diagnosis of hypertension or type 2 diabetes, recorded in the preceding 12 months (excluding those with pre-existing cardiovascular disease, chronic kidney disease, familial hypercholesterolaemia or type 1 diabetes) who have had a consultation for full formal cardiovascular disease risk assessment between 3 months before or 3 months after date of diagnosis. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM132

  3. The SENSIMED Triggerfish contact lens sensor for continuous 24-hour recording of ocular dimensional changes in people with or at risk of developing glaucoma (MIB14)

    NICE has developed a Medtech Innovation Briefing (MIB) on the SENSIMED Triggerfish contact lens sensor for continuous 24-hour recording of ocular dimensional

  4. Physical activity and the environment (NG90)

    This guideline covers how to improve the physical environment to encourage and support physical activity. The aim is to increase the general population’s physical activity levels.

  5. COVID-19 rapid guideline: managing COVID-19 (NG191)

    This guideline covers managing COVID-19 in babies, children, young people and adults in community and hospital settings. It includes recommendations on communication, assessment, therapeutics for COVID-19, non-invasive respiratory support, preventing and managing acute complications, and identifying and managing co-infections.

  6. Epilepsies in children, young people and adults (NG217)

    This guideline covers diagnosing and managing epilepsy in children, young people and adults in primary and secondary care, and referral to tertiary services. It aims to improve diagnosis and treatment for different seizure types and epilepsy syndromes, and reduce the risks for people with epilepsy.

  7. Type 2 diabetes foot problems: Prevention and management of foot problems (CG10)

    This guidance has been updated and replaced by NICE guideline NG19.

  8. Coexisting severe mental illness and substance misuse: community health and social care services (NG58)

    This guideline covers how to improve services for people aged 14 and above who have been diagnosed as having coexisting severe mental illness and substance misuse. The aim is to provide a range of coordinated services that address people’s wider health and social care needs, as well as other issues such as employment and housing.

  9. Clostridium difficile infection: risk with broad-spectrum antibiotics (ESMPB1)

    Summary of the evidence on the risk of using broad-specturm antibiotics associated with clostridium difficile infection

  10. Biomarker tests to help diagnose preterm labour in women with intact membranes (HTG476)

    Evidence-based recommendations on biomarker tests to help diagnose preterm labour in women with intact membranes. The tests are Actim Partus, PartoSure and the Rapid fetal fibronectin (fFN) 10Q Cassette Kit (at thresholds other than 50 nanograms/millilitre).

  11. Stroke rehabilitation in adults (NG236)

    This guideline covers rehabilitation after stroke for over 16s. It aims to ensure people are assessed for common problems and conditions linked to stroke, and get the care and therapy they need. It includes recommendations on the organisation and delivery of rehabilitation in hospital and the community.

  12. Point-of-care creatinine devices to assess kidney function before CT imaging with intravenous contrast (HTG530)

    Evidence-based recommendations on point-of-care creatinine devices to assess kidney function before CT imaging with intravenous contrast. The tests are ABL800 FLEX, i-STAT Alinity and StatSensor, ABL90 FLEX PLUS, Dri chem NX500, epoc Blood Analysis System, and Piccolo Xpress.

  13. Antenatal care (QS22)

    This quality standard covers the routine antenatal care that women and their babies should receive during pregnancy. It describes high-quality care in priority areas for improvement.

  14. Postnatal care (QS37)

    This quality standard covers routine postnatal care in the first 8 weeks after birth. It describes high-quality care in priority areas for improvement.

  15. Meningitis (bacterial) and meningococcal disease: recognition, diagnosis and management (NG240)

    This guideline covers recognising, diagnosing and managing bacterial meningitis and meningococcal disease in babies, children, young people and adults. It aims to reduce death and disability by helping healthcare professionals recognise meningitis and treat it quickly and effectively.